CN100439365C - 用作蛋白激酶抑制剂的化合物和组合物 - Google Patents
用作蛋白激酶抑制剂的化合物和组合物 Download PDFInfo
- Publication number
- CN100439365C CN100439365C CNB2004800245751A CN200480024575A CN100439365C CN 100439365 C CN100439365 C CN 100439365C CN B2004800245751 A CNB2004800245751 A CN B2004800245751A CN 200480024575 A CN200480024575 A CN 200480024575A CN 100439365 C CN100439365 C CN 100439365C
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- pyrrolo
- pyrimidine
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49853203P | 2003-08-28 | 2003-08-28 | |
| US60/498,532 | 2003-08-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1842529A CN1842529A (zh) | 2006-10-04 |
| CN100439365C true CN100439365C (zh) | 2008-12-03 |
Family
ID=34519982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004800245751A Expired - Fee Related CN100439365C (zh) | 2003-08-28 | 2004-08-27 | 用作蛋白激酶抑制剂的化合物和组合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7338957B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1658290A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007504159A (cg-RX-API-DMAC7.html) |
| CN (1) | CN100439365C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004283093B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0414049A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2536535A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06002347A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005039486A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| WO2006124462A2 (en) * | 2005-05-13 | 2006-11-23 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
| WO2007113505A2 (en) * | 2006-03-30 | 2007-10-11 | The University Court Of The University Of Edinburgh | Culture medium containing kinase inhibitors. and uses thereof |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| BRPI0710496A2 (pt) | 2006-04-07 | 2011-08-16 | Novartis Ag | combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase |
| WO2008147831A1 (en) * | 2007-05-23 | 2008-12-04 | Smithkline Beecham Corporation | Anthranilamides |
| EP2540727B1 (en) | 2007-08-02 | 2018-07-25 | Millennium Pharmaceuticals, Inc. | Sulfamoylating reagent |
| EP2188292B1 (en) * | 2007-08-08 | 2013-05-29 | GlaxoSmithKline Intellectual Property Development Limited | 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer |
| BRPI0819453A2 (pt) | 2007-11-28 | 2014-10-07 | Dana Farber Cancer Inst Inc | Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit |
| AU2009206775A1 (en) * | 2008-01-22 | 2009-07-30 | Merck Patent Gmbh | Protein kinase inhibitors and use thereof |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| EP2430026A1 (en) | 2009-05-14 | 2012-03-21 | Millennium Pharmaceuticals, Inc. | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| US8728763B2 (en) | 2009-08-11 | 2014-05-20 | Response Genetics | Methods, primers, probes and kits useful for the detection of BRAF mutations |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN104876879B (zh) * | 2015-04-14 | 2018-05-18 | 中国科学院合肥物质科学研究院 | 一种bcr-abl激酶抑制剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335849A (zh) * | 1998-09-18 | 2002-02-13 | 巴斯福股份公司 | 作为蛋白激酶抑制剂的吡咯并嘧啶 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2223081C (en) * | 1995-06-07 | 2001-03-06 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
| US6610688B2 (en) * | 1999-12-21 | 2003-08-26 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| US20040235867A1 (en) * | 2001-07-24 | 2004-11-25 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
-
2004
- 2004-08-26 US US10/927,992 patent/US7338957B2/en not_active Expired - Fee Related
- 2004-08-27 WO PCT/US2004/027997 patent/WO2005039486A2/en not_active Ceased
- 2004-08-27 EP EP04816834A patent/EP1658290A4/en not_active Withdrawn
- 2004-08-27 MX MXPA06002347A patent/MXPA06002347A/es active IP Right Grant
- 2004-08-27 JP JP2006524903A patent/JP2007504159A/ja active Pending
- 2004-08-27 CA CA002536535A patent/CA2536535A1/en not_active Abandoned
- 2004-08-27 CN CNB2004800245751A patent/CN100439365C/zh not_active Expired - Fee Related
- 2004-08-27 BR BRPI0414049-4A patent/BRPI0414049A/pt not_active IP Right Cessation
- 2004-08-27 AU AU2004283093A patent/AU2004283093B2/en not_active Ceased
-
2008
- 2008-01-07 US US11/970,278 patent/US20080108616A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335849A (zh) * | 1998-09-18 | 2002-02-13 | 巴斯福股份公司 | 作为蛋白激酶抑制剂的吡咯并嘧啶 |
Non-Patent Citations (1)
| Title |
|---|
| Activation of tyrosine Kinases in cancer. VLAHOVIC G et al.Oncologist,Vol.8 No.6. 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US7338957B2 (en) | 2008-03-04 |
| EP1658290A2 (en) | 2006-05-24 |
| CN1842529A (zh) | 2006-10-04 |
| WO2005039486A3 (en) | 2006-03-16 |
| EP1658290A4 (en) | 2009-04-15 |
| US20050159391A1 (en) | 2005-07-21 |
| US20080108616A1 (en) | 2008-05-08 |
| BRPI0414049A (pt) | 2006-10-24 |
| CA2536535A1 (en) | 2005-05-06 |
| JP2007504159A (ja) | 2007-03-01 |
| AU2004283093B2 (en) | 2009-02-26 |
| WO2005039486A2 (en) | 2005-05-06 |
| AU2004283093A1 (en) | 2005-05-06 |
| MXPA06002347A (es) | 2006-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080108616A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| KR102531036B1 (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 | |
| CN104781252B (zh) | 用作IL‑12、IL‑23和/或IFNα应答调节剂的被烷基‑酰胺取代的吡啶化合物 | |
| EP2699564B1 (en) | Substituted pyrimidinyl-pyrroles active as kinase inhibitors | |
| CA2779105C (en) | Kinase inhibitors | |
| JP4917041B2 (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| CN115626919A (zh) | 哒嗪基噻唑甲酰胺类化合物 | |
| CN110191887B (zh) | IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂 | |
| CN101500574A (zh) | 用作蛋白激酶抑制剂的化合物和组合物 | |
| CN101282975A (zh) | 作为蛋白激酶抑制剂的化合物和组合物 | |
| KR102477063B1 (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 | |
| CN104884454A (zh) | 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物 | |
| CA2958503A1 (en) | Indazole compounds as fgfr kinase inhibitor, preparation and use thereof | |
| CN101175753A (zh) | 作为蛋白激酶抑制剂的化合物和组合物 | |
| CA2619365A1 (en) | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators | |
| CN101166732B (zh) | 氰基吡啶衍生物及其作为药物的应用 | |
| CN104837844B (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
| JP2016526545A (ja) | スルホキシイミン置換キナゾリンならびにmnk1および/またはmnk2キナーゼ阻害薬としてのその使用 | |
| JP2022533182A (ja) | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 | |
| CN109810098A (zh) | 含有酞嗪-1(2h)-酮结构的parp-1和pi3k双靶点抑制剂 | |
| CN101208338A (zh) | 氮杂苯并咪唑衍生物,它们的制备以及作为抗癌剂的应用 | |
| ES2418457T3 (es) | Derivados de 1-(7-(hexahidropirrolo[3,4-c]pirrol-2(1H)-il)quinolin-4-il)-3-(pirazin-2-il)urea y compuestos relacionados como inhibidores de glucógeno sintasa cinasa 3 (GSK-3) | |
| WO2019109647A1 (zh) | 含有吡啶并嘧啶结构的parp和pi3k双靶点抑制剂 | |
| CN101056632B (zh) | 用作蛋白激酶抑制剂的化合物和组合物 | |
| JP2009501176A (ja) | グリコーゲンシンターゼキナーゼ3阻害薬としてのピリダジン化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081203 Termination date: 20110827 |